# Gain Therapeutics, Inc.: overview

GANX · Nasdaq · CIK 1819411 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ganx.md) · [Financials](/companies/ganx/financials.md) · [Filings](/companies/ganx/filings.md) · [Insiders](/companies/ganx/insiders.md)

Latest reported revenue: [$0](/filings/0001558370-25-003823.md) for Q4 FY2023, three months to 2023-12-31, from the 10-K filed Mar 27, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001558370-25-003823).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.17)](/filings/0001104659-25-110347.md) | not reported | [(0.16)](/filings/0001104659-26-058649.md) | [(0.19)](/filings/0001104659-26-094048.md) | [(0.15)](/filings/0001104659-25-110347.md) | not reported | [(0.13)](/filings/0001104659-26-058649.md) | [(0.11)](/filings/0001104659-26-094048.md) |
| Free cash flow | $k | [(6,076) d](/filings/0001104659-25-110347.md) | [(3,456) d](/filings/0001104659-26-035188.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001558370-23-004460.md) | [0.1](/filings/0001558370-24-003943.md) | [0.1](/filings/0001558370-25-003823.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(10323.6%)](/filings/0001558370-23-004460.md) | [(13402.5%)](/filings/0001558370-24-003943.md) | [(40328.3%)](/filings/0001558370-25-003823.md) | not reported | not reported |
| Net margin | % | [(10371.7%)](/filings/0001558370-23-004460.md) | [(13262.0%)](/filings/0001558370-24-003943.md) | [(40354.3%)](/filings/0001558370-25-003823.md) | not reported | not reported |
| Diluted EPS | $ per share | [(1.37)](/filings/0001558370-23-004460.md) | [(1.48)](/filings/0001558370-24-003943.md) | [(1.71)](/filings/0001558370-25-003823.md) | [(0.89)](/filings/0001104659-26-035188.md) | [(0.61)](/filings/0001104659-26-035188.md) |
| Free cash flow | $m | [(12.5)](/filings/0001558370-23-004460.md) | [(14.8)](/filings/0001558370-24-003943.md) | [(18.9)](/filings/0001558370-25-003823.md) | [(18.9)](/filings/0001104659-26-035188.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ganx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $3.9m | 1,923,546 |  | Added +153,758 |
| [Potomac Capital Management, Inc.](/funds/1418746.md) | 2026-06-30 | $1.9m | 946,400 |  | Reduced −62,200 |
| [DME Capital Management, LP](/funds/1489933.md) | 2026-06-30 | $1.1m | 566,130 |  | Unchanged |
| [JONES FINANCIAL COMPANIES LLLP](/funds/815917.md) | 2026-06-30 | $1.1m | 608,592 |  | Reduced −23,023 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $974.9k | 480,269 |  | Added +80,383 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $921.4k | 453,501 |  | Added +6,159 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $558.2k | 274,957 |  | Added +49,911 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $470.0k | 231,534 |  | Added +1,555 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $436.5k | 215,012 |  | Reduced −5,477 |
| [Stratos Wealth Partners, LTD.](/funds/1612865.md) | 2026-06-30 | $406.0k | 200,000 |  | Added +68,379 |

## Recent filings

[All 240 filings](/companies/ganx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 17:00 ET | [8-K](/filings/0001104659-26-119673.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-119673 |
| 2026-10-01 | 09:16 ET | [8-K](/filings/0001104659-26-112624.md) | 8.01 Other events | 0001104659-26-112624 |
| 2026-09-28 | 16:30 ET | [8-K](/filings/0001104659-26-111391.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-111391 |
| 2026-08-11 | 16:07 ET | [10-Q](/filings/0001104659-26-094048.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094048 |
| 2026-08-11 | 16:05 ET | [8-K](/filings/0001104659-26-094041.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-094041 |
| 2026-07-16 | 07:53 ET | [8-K](/filings/0001104659-26-084086.md) | 8.01 Other events | 0001104659-26-084086 |
| 2026-06-29 | 16:21 ET | [8-K](/filings/0001104659-26-078848.md) | 8.01 Other events | 0001104659-26-078848 |
| 2026-06-25 | 17:00 ET | [8-K](/filings/0001104659-26-077820.md) | 5.07 Shareholder vote results | 0001104659-26-077820 |
| 2026-05-26 | 09:26 ET | [8-K](/filings/0001104659-26-066062.md) | 8.01 Other events | 0001104659-26-066062 |
| 2026-05-11 | 16:08 ET | [10-Q](/filings/0001104659-26-058649.md) | Quarterly report, period 2026-03-31 | 0001104659-26-058649 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-035188.md), filed Mar 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1819411
- Tickers: GANX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 17:20 ET. No prices; not investment advice.